Infliximab ELISA (mAb-based) is for precise measurement of free Infliximab in serum and plasma.

• Dynamic Range: 6 - 200 ng/mL
• Sensitivity: 2 ng/mL
• Incubation: 2 hours

The drug Infliximab (trade names Remicade®, Remsima®, and Inflectra®) is a chimeric monoclonal antibody and used to treat auto-immune disorders. Infliximab reduces the amount of active human tumor necrosis factor alpha (hTNF-α) in the patient by binding to it and preventing it from signaling the receptors for TNF-α on the surface of various cell types. TNF-α is one of the key cytokines that triggers and sustains the inflammatory reactions. Infliximab is used for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis. The specificity of this testsystem is achieved by using a monoclonal antibody named "Peri-1 mAb" for the coating of the microtiter plate. This antibody is specific for Infliximab only (regardless whether Remicade®, Remsima®, or Inflectra®) and does not cross react with other TNF-α catchers. In this context, identification of biomarkers for (non-)response and risk factors for adverse drug reactions relating to serum concentrations and therapeutic drug monitoring of Infliximab would be very helpful.